Research Topics
| P A VaseySummaryAffiliation: University of Glasgow Country: UK Publications
|
Detail Information
Publications
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II CommitteeP A Vasey
CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
Clin Cancer Res 5:83-94. 1999..The recommended Phase II dose is 280 mg/m2 every 3 weeks. Studies are planned in colorectal, NSCLC, and breast cancer patients...- Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancerP A Vasey
Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom
J Clin Oncol 20:1562-9. 2002.... - Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials GroupP A Vasey
Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom
J Clin Oncol 17:2069-80. 1999..The primary end point was the incidence of severe fluid retention that necessitated treatment withdrawal... 
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancerP A Vasey
CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT
Br J Cancer 84:170-8. 2001..3-19.1). Recommended doses are carboplatin AUC 5 (via(51)Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m(2). A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment...- A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancerV J O'Neill
Cancer Research UK Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow GL1 6NT, UK
Br J Cancer 86:1385-90. 2002..The predefined maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m(-2), carboplatin AUC 4, docetaxel 75 mg m(-2)), warrants further study... - Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategiesP A Vasey
Cancer Research UK, Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
Br J Cancer 89:S23-8. 2003.... - Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancerP A Vasey
Department of Medical Oncology, Cancer Research UK, West of Scotland Clinical Trials Unit, Beatson Oncology Centre, E Block, Western Infirmary, Glasgow, G11 6NT, Scotland, UK
Br J Cancer 87:1072-8. 2002..These findings establish a recommended dose of docetaxel 75 mg m(-2) in combination with cyclophosphamide 600 mg m(-2) every three weeks for phase II evaluation... - A phase I and pharmacokinetic study of LY231514, the multitargeted antifolateA C McDonald
CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
Clin Cancer Res 4:605-10. 1998..9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h. When given by this schedule, LY231514 is tolerable, and Phase II studies are in progress... - A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancersP A Vasey
CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, Scotland G11 6NT, UK
Br J Cancer 98:1774-80. 2008..Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy... 
Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trialS V Barrett
Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
Ann Oncol 19:898-902. 2008..We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients...- SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancerP A Vasey
CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
Br J Cancer 94:62-8. 2006..Larger phase III studies are required to test these combinations... - "Dose dense" chemotherapy in ovarian cancerP A Vasey
School of Medicine, University of Queensland, Herston, Queensland, Australia
Int J Gynecol Cancer 15:226-32. 2005..This article will review the clinical data supporting dose density as a therapeutic maneuver in ovarian cancer... - A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancerP A Vasey
Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
Br J Cancer 89:1843-8. 2003..The convenience and improved safety profile of capecitabine compared with intravenous. regimens make it an ideal agent for administration in the outpatient setting... - Ovarian cancer: front-line standard treatment in 2008P A Vasey
Division of Medicine, University of Queensland, Brisbane, Australia
Ann Oncol 19:vii61-6. 2008 - ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinomaP A Vasey
Division of Oncology, Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland 4029, Australia
Ann Oncol 16:i13-5. 2005